0

Month: December 2016

Heart Health: Staggering Statistics Urge Prevention

Heart HealthAs the number of Americans with heart disease increases, medical and health experts have been forced to come to terms with the enormous and far-reaching impacts of cardiovascular disease: the primary killer in the U.S., responsible for approximately 1 in every 4 deaths. Data recently released by the National Health Center for Health Statistics indicates that heart disease took over 633,000 lives in the past year—a 0.9 percent increase from the previous year, and the first upward spike since 1999.

A sustained rising trend has prompted scientists to evaluate and assess the methods and protocols that have traditionally been used to treat heart disease; Dr. Steven Houser, president of the American Heart Association, has articulated the need for more progress—with a targeted focus on prevention. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Linking Sleep Disturbance & Obesity

linking sleep Recent research corroborates theories regarding the link between sleep disturbance and a range of conditions, including obesity. In the journal Nature Genetics, a group of scientists recently published evidence from a study that assessed lifestyle and environmental factors, in addition to inherited traits that affect sleep disturbance and duration—ultimately concluding that areas of the genome are linked to sleep disturbance. The team also discovered genetic links between higher levels of excessive sleepiness during the daytime, and increased measures of obesity: including body mass index and waist circumference.

While there have been previously observed connections between sleep disorders and conditions in epidemiological studies, these biological links have never before been identified at a molecular level. Dr. Martin K. Rutherr, clinical senior lecturer in cardiometabolic medicine at University of Manchester and one of the senior authors of the paper, discussed the ways in which this clinical science can help take ‘an important step forward.’ Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stanley Hazen, MD, PhD Joins Roster of Expert Faculty for The 12th Annual CMHC

The Cardiometabolic Health Congress has announced Stanley Hazen, MD, PhD, Head of the Section for Preventive Cardiology and Rehabilitation of the Cleveland Clinic as its Keynote speaker for the 12th Annual CMHC, taking place October 4-7, 2017, at the Sheraton in Boston, MA. Specializing in preventive cardiovascular care, including the treatment of hyperlipidemia, diabetes, hypertension, and obesity, Dr. Hazen will discuss his groundbreaking work concerning gut microbes as a factor and therapeutic target in cardiometabolic diseases. Dr. Hazen has received numerous awards including election to membership in honorary societies in science and clinical arenas alike and also serves as reviewer and/or is on the editorial board for many scientific journals, including Circulation and the Journal of Lipid Research.

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

2017 ADA Standards of Medical Care in Diabetes Emphasize Psychological Health and Personalized Treatment Options

The newly published 2017 Standards of Medical Care in Diabetes by the American Diabetes Association emphasize psychological health, access to care, expanded and personalized treatment options, as well as hypoglycemia tracking in patients with diabetes as critical areas of focus.

In addition to screening, diagnosis, and treatment options, including metabolic surgery, that will provide better outcomes for patients with diabetes and information to improve the prevention/delay of type 2 diabetes, the guidelines also include data from a report that focused on beta-cell dysfunction and describes approaches to clarify specific subtypes of diabetes to facilitate personalized care.

The Standards also specifically include a recommendation to consider the use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death.

References:

ADA: 2017 Standards of Medical Care in Diabetes Released.

2017 Standards of Medical Care in Diabetes.

Boehringer Ingelheim and Lilly welcome new recommendation for Jardiance® (empagliflozin) tablets in updated American Diabetes Association’s 2017 Standards.

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Heart Disease & Pregnancy: Careful Considerations

heart disease and pregnancyA recent report published through a study at Oxford University reveals a number of cases involving pregnant women and heart disease, during which physicians have failed to intervene and treat the cardiovascular condition.

Because pregnancy and childbirth often exert extra strain on the heart, which is exacerbated by pre-existing and underlying conditions, several deaths of fatal heart attacks have occurred without warning. Pregnancy itself stresses the heart and circulatory system, as blood volume increases by up to 50%, in order to nourish the growing baby. Moreover, the amount of blood pumped by the heart also increases by up to 50%. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Simple & Preventive Changes to Combat Heart Disease

Cardiovascular disease has the highest mortality rate in the United States, and billions of dollars are given to pharmaceutical industries each year in order to combat and reduce risks.

Yet recent research on cardiovascular risk factors offers renewed hope and optimism regarding heart disease, demonstrating a number of simple life changes to implement in order to prevent the onset of cardiovascular disease. Changing behavior can significantly lower risks, even for those genetically predisposed to heart disease—though it has long been thought that these factors were outside one’s control. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

First “Follow-On” Insulin Now Available in the United States

One year after the US FDA granted approval to the first “follow-on” insulin, the long-acting insulin glargine product has been officially launched in the United States. Approved as a follow-on and not a biosimilar, the long-acting insulin glargine has already been made available in Europe, and is available as a 100 Units/mL strength in 3-mL prefilled pens. It can be used in both children and adults with type 1 diabetes and adults with type 2 diabetes.

References:

Basaglar now available for type 1, type 2 diabetes.

FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes.

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Misperceptions About Obesity Persist

misconceptions about obesityAccording to a recent survey of 1509 Americans conducted by the American Society for Metabolic and Bariatric Surgery (ASMBS) and NORC at the University of Chicago, 81% cited obesity (along with cancer) as the most serious health threat in our country. Diabetes (72%), heart disease (72%), mental illness (65%), and HIV/AIDS (46%) followed on the list.

The majority (94%) agreed that obesity increased the risk for early death, even without other health issues. Most also believed diet and exercise alone were the most effective methods for long-term weight loss, with 60% indicating they were more effective than bariatric surgery. One-third of those surveyed who were obese reported having never spoken to a physician about their weight, and only 12% of those for whom bariatric surgery may be an option said their physician made the suggestion. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Eugene Braunwald, MD joins roster of expert faculty for the 12th Annual CMHC

Just Announced –

Eugene Braunwald, MD joins roster of expert faculty for the 12th Annual CMHC – October 4-7, 2017, Boston, MA

Dr. Braunwald, Professor at Harvard Medical School, is a world-renowned expert in the field of cardiovascular medicine and is believed to be the most frequently cited author in the field of cardiology, with more than 1000 publications in peer-reviewed journals. His landmark research includes the identification of hypertrophic cardiomyopathy as a clinical entity. As Founder and Chairman of the TIMI Study Group, one of their many achievements was the PROVE-IT TIMI 22 Trial, which demonstrated the benefit of intensive reduction of LDL cholesterol by statin therapy. Dr. Braunwald will be joining a panel at the 12th Annual CMHC that includes Drs. Christie Ballantyne, Paul Ridker, and Marc Sabatine to discuss the clinical trials FOURIER, REVEAL, and CANTOS.

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Eugene Braunwald, MD Joins Roster of Expert Faculty for The 12th Annual CMHC

Dr. Braunwald, Professor at Harvard Medical School, is a world-renowned expert in the field of cardiovascular medicine and is believed to be the most frequently cited author in the field of cardiology, with more than 1000 publications in peer-reviewed journals. His landmark research includes the identification of hypertrophic cardiomyopathy as a clinical entity. As Founder and Chairman of the TIMI Study Group, one of their many achievements was the PROVE-IT TIMI 22 Trial, which demonstrated the benefit of intensive reduction of LDL cholesterol by statin therapy. Dr. Braunwald will be joining a panel at the 12th Annual CMHC that includes Drs. Christie Ballantyne, Paul Ridker, and Marc Sabatine to discuss the clinical trials FOURIER, REVEAL, and CANTOS.

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn